Evidence map›Paper›PMID 33524402›Full record

GuidelineGastroenterology2021

AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review.

Shailja C Shah, Prasad G Iyer, Steven F Moss

Registry-linked trialAbstract readPractice GuidelineReview
In one paragraph

Guideline in Gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06318104 (Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Amoxicillin 1g + Clarithromycin 500 mg and Tegoprazan 50 mg vs Amoxicillin 1g + Clarithromycin 500 mg and Esomeprazole 40 mg Twice a Day for 14 Days), which is not on this map. Cited by 134 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
134citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06318104 phase4unknown statusnot on this mapstarted 2024, after this paper: background citation

Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Amoxicillin 1g + Clarithromycin 500 mg and Tegoprazan 50 mg vs Amoxicillin 1g + Clarithromycin 500 mg and Esomeprazole 40 mg Twice a Day for 14 Days

TypeinterventionalSponsorHospital General de México Dr. Eduardo LiceagaRan2024 to 2025Enrolled160ConditionsHelicobacter Pylori InfectionArmsTegoprazan, Esomeprazole 40mg
3 · Its place in the literature

Who cites it

134 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. [Evidence-Based Guidelines for the Diagnosis and Treatment ofThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2026
    Guideline
  4. Pooled it
  5. First regional consensus on the management ofWorld journal of gastroenterology · 2025
    Guideline
  6. Pooled it
  7. Pooled it
  8. Guideline
  9. Vonoprazan-amoxicillin dual therapy forSaudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
    Pooled it
  10. Trial
  11. Trial
  12. Rech. f. & Esfand as adjunctive therapy for eradication: a randomized controlled trial.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025
    Trial
  13. Trial
  14. Trial
  15. Trial
  16. Frontiers in cellular and infection microbiology · 2022
    Trial
  17. Article
  18. Review
  19. Article
  20. Review

74 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Shailja C ShahGastroenterology Section, VA San Diego Healthcare System, La Jolla, California; VA Tennessee Valley Health System, Nashville, Tennessee; Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address: shailja.c.shah@vumc.org.
Prasad G IyerDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Steven F MossDivision of Gastroenterology, Warren Alpert Medical School of Brown University, Providence, Rhode Island.

Funding

Learning Health System Scholar Program at VanderbiltK12HS026395 · AHRQ · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ROTHMAN, RUSSELL L., ROUMIE, CHRISTIANNE L. · 2018 to 2022
$2.7M
Optimization of Helicobacter pylori-related Disease Outcomes in VeteransIK2CX002027 · VA · VETERANS HEALTH ADMINISTRATION · PI SHAILJA C SHAH · 2020 to 2026
–
AHRQ HHS K12 HS026395CSRD VA IK2 CX002027
6 · The paper itself

Abstract

The purpose of this CPU Expert Review is to provide clinicians with guidance on the management of Helicobacter pylori after an initial attempt at eradication therapy fails, including best practice advice on specific regimen selection, and consideration of patient and systems factors that contribute to treatment efficacy. This Expert Review is not a formal systematic review, but is based upon a review of the literature to provide practical advice. No formal rating of the strength or quality of the evidence was carried out. Accordingly, a combination of available evidence and consensus-based expert opinion were used to develop these best practice advice statements.

Indexed as

AlgorithmsAnti-Bacterial AgentsBenchmarkingClinical Decision-MakingClinical Decision RulesConsensusDrug Resistance, BacterialDrug Therapy, CombinationEvidence-Based MedicineGastroenterologyHelicobacter InfectionsHelicobacter pyloriHumansRemission InductionTreatment OutcomeAnti-Bacterial AgentsAdherenceAntibioticsClinical ManagementCYP2C19Gastro NeoplasmProton Pump Inhibitor

Identifiers

PMID33524402
PMCPMC8281326

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.